Skip to main content
SpringerLink
Log in

Risks of adverse events with niacin/laropiprant

  • Clinical study
  • Published:
Reactions Weekly Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Notes

  1. Heart Protection Study 2–Treatment of HDL to Reduce the Incidence of Vascular Events (Clinical Trial Profile 700022418)

  2. Atherothrombosis Intervention in Metabolic syndrome with low HDL/High triglycerides: Impact on Global Health 0utcomes

References

  1. HPS2-THRIVE Collaborative Group. Effects of extended-release niacin with laropiprant in high-risk patients. New England Journal of Medicine 371: 203-12, No. 3, 17 Jul 2014. Available from: URL: http://doi.org/10.1056/NEJMoa1300955

    Article  Google Scholar 

  2. Lloyd-Jones DM. Niacin and HDL Cholesterol - Time to Face Facts. New England Journal of Medicine 371: 271-3, No. 3, 17 Jul 2014. Available from: URL: http://doi.org/10.1056/NEJMe1406410

    Article  PubMed  Google Scholar 

  3. Anderson TJ, et al. Safety Profile of Extended-Release Niacin in the AIM-HIGH Trial. New England Journal of Medicine 371: 288-90, No. 3, 17 Jul 2014. Available from: URL: http://doi.org/10.1056/NEJMc1311039

    Article  PubMed  Google Scholar 

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Risks of adverse events with niacin/laropiprant. Reactions Weekly 1514, 4 (2014). https://doi.org/10.1007/s40278-014-2546-2

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40278-014-2546-2

Search

Navigation